Treating very early rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 5, 2006, Pages 849-863

  Raza, Karim ^b   Buckley, Caitriona E ^b   Salmon, Mike ^b   Buckley, Christopher D ^a  

^a Institute of Biomedical Research   (United Kingdom)

^b NONE

Author keywords

anti TNF therapy; DMARD; early arthritis; remission; rheumatoid arthritis; synovitis; therapy

Indexed keywords

CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADD ON THERAPY; ARTHROPATHY; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIBODIES; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; HUMANS; LEUKOCYTES; NEUTROPHILS; PEPTIDES, CYCLIC; REMISSION INDUCTION; RHEUMATOID FACTOR; SYNOVITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748669058     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.05.005     Document Type: Review

References (89)

1. Tunn E.J., and Bacon P.A. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. British Journal of Rheumatology 32 (1993) 97-103
2. Harrison B.J., Symmons D.P., Brennan P., et al. Natural remission in inflammatory polyarthritis: issues of definition and prediction. British Journal of Rheumatology 35 (1996) 1096-1100
3. Symmons D., Turner G., Webb R., et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41 (2002) 793-800
4. Wolfe F., and Cathey M.A. The assessment and prediction of functional disability in rheumatoid arthritis. The Journal of Rheumatology 18 (1991) 1298-1306
5. Wolfe F., and Hawley D.J. The long term outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. The Journal of Rheumatology 25 (1998) 2108-2117
6. del Rincon I.D., Williams K., Stern M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis and Rheumatism 44 (2001) 2737-2745
7. Bacon P.A., and Townend J.N. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis and Rheumatism 44 (2001) 2707-2710
8. Scott D.L., Symmons D.P., Coulton B.L., and Popert A.J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1 (1987) 1108-1111
9. Bukhari M., Harrison B., Lunt M., et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis and Rheumatism 44 (2001) 1248-1253
10. Welsing P.M., Landewe R.B., van Riel P.L., et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism 50 (2004) 2082-2093
11. Wick M.C., Lindblad S., Klareskog L., and Van Vollenhoven R.F. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description. Annals of the Rheumatic Diseases 63 (2004) 848-852
12. Conaghan P.G., O'Connor P., McGonagle D., et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis and Rheumatism 48 (2003) 64-71
13. Irvine S., Munro R., and Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Annals of the Rheumatic Diseases 58 (1999) 510-513
14. Mikuls T.R., and O'Dell J. The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis and Rheumatism 43 (2000) 464-465
15. Salmon M., Scheel-Toellner D., Huissoon A.P., et al. Inhibition of T cell apoptosis in the rheumatoid synovium. The Journal of Clinical Investigation 99 (1997) 439-446
16. Pilling D., Akbar A.N., Girdlestone J., et al. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. European Journal of Immunology 29 (1999) 1041-1050
17. Salmon M., Pilling D., Borthwick N.J., and Akbar A.N. Inhibition of T cell apoptosis - a mechanism for persistence in chronic inflammation. The Immunologist 5 (1997) 87-92
18. Buckley C.D., Pilling D., Lord J.M., et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends in Immunology 22 (2001) 199-204
19. Buckley C.D., Amft N., Bradfield P.F., et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. Journal of Immunology (Baltimore, Md.: 1950) 165 (2000) 3423-3429
20. Smolen J.S., Aletaha D., and Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. Arthritis and Rheumatism 52 (2005) 2975-2983
21. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism 41 (1998) 1552-1563
22. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
23. Schumacher H.R., and Kitridou R.C. Synovitis of recent onset. A clinicopathologic study during the first month of disease. Arthritis and Rheumatism 15 (1972) 465-485
24. Schumacher Jr. H.R., Bautista B.B., Krauser R.E., et al. Histological appearance of the synovium in early rheumatoid arthritis. Seminars in Arthritis and Rheumatism 23 (1994) 3-10
25. Konttinen Y.T., Bergroth V., Nordstrom D., et al. Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis. Annals of the Rheumatic Diseases 44 (1985) 549-555
26. Raza K., Falciani F., Curnow S.J., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Research and Therapy 7 (2005) R784-R795
27. Firestein G.S. Pathogenesis of rheumatoid arthritis: how early is early?. Arthritis Research and Therapy 7 (2005) 157-159
28. Cush J.J. Early arthritis clinics: if you build it will they come?. The Journal of Rheumatology 32 (2005) 203-207
29. The HERA study group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. The American Journal of Medicine 98 (1995) 156-168
30. van der Heide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial. Annals of Internal Medicine 124 (1996) 699-707
31. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
32. Landewe R.B., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis and Rheumatism 46 (2002) 347-356
33. Mottonen T., Hannonen P., Leirisalo-Repo M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353 (1999) 1568-1573
34. Korpela M., Laasonen L., Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis and Rheumatism 50 (2004) 2072-2081
35. Proudman S.M., Conaghan P.G., Richardson C., et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis and Rheumatism 43 (2000) 1809-1819
36. Dougados M., Combe B., Cantagrel A., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases 58 (1999) 220-225
37. Verstappen S.M., Jacobs J.W., Bijlsma J.W., et al. Five-year follow-up of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis and Rheumatism 48 (2003) 1797-1807
38. Maillefert J.F., Combe B., Goupille P., et al. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Annals of the Rheumatic Diseases 62 (2003) 764-766
39. Kirwan J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The New England Journal of Medicine 333 (1995) 142-146
40. Svensson B., Boonen A., Albertsson K., et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis and Rheumatism 52 (2005) 3360-3370
41. Harris Jr. E.D. Prednisolone in early rheumatoid arthritis: an antiinvasive effect. Arthritis and Rheumatism 52 (2005) 3324-3325
42. Capell H.A., Madhok R., Hunter J.A., et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases 63 (2004) 797-803
43. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine 343 (2000) 1586-1593
44. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 50 (2004) 3432-3443
45. Breedveld F.C., Kavanaugh A.F., Cohen S.B., et al. Early treatment of rheumatoid arthritis (RA) with adalimumab (HUMIRA) plus methotrexate vs. adalimumab alone or methotrexate alone: The Premier study. Arthritis and Rheumatism 50 (2004) 4096-4097
46. Conaghan P.G., Quinn M.A., O'Connor P., et al. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?. Arthritis and Rheumatism 46 (2002) 1971-1972
47. Quinn M.A., Conaghan P.G., O'Connor P.J., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 52 (2005) 27-35
48. Goekoop-Ruiterman Y.P., Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis and Rheumatism 52 (2005) 3381-3390
49. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nature Immunology 6 (2005) 1191-1194
50. Takemura S., Braun A., Crowson C., et al. Lymphoid neogenesis in rheumatoid synovitis. Journal of Immunology (Baltimore, Md.: 1950) 167 (2001) 1072-1080
51. Nishikawa S.I., Hashi H., Honda K., et al. Inflammation, a prototype for organogenesis of the lymphopoietic/hematopoietic system. Current Opinion in Immunology 12 (2000) 342-345
52. Nanki T., Hayashida K., El Gabalawy H.S., et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. Journal of Immunology (Baltimore, Md.: 1950) 165 (2000) 6590-6598
53. Suzuki Y., Rahman M., and Mitsuya H. Diverse transcriptional response of CD4(+) T cells to stromal cell-derived factor (SDF)-1: cell survival promotion and priming effects of SDF-1 on CD4(+) T cells. Journal of Immunology (Baltimore, Md.: 1950) 167 (2001) 3064-3073
54. Scheel-Toellner D., Wang K., Henriquez N.V., et al. Cytokine-mediated inhibition of apoptosis in non-transformed T cells and neutrophils can be dissociated from protein kinase B activation. European Journal of Immunology 32 (2002) 486-493
55. Reparon-Schuijt C.C., van Esch W.J., van Kooten C., et al. Regulation of synovial B cell survival in rheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. Arthritis and Rheumatism 43 (2000) 1115-1121
56. Brennan F., and Foey A. Cytokine regulation in RA synovial tissue: role of T cell/macrophage contact-dependent interactions. Arthritis Research 4 supplement 3 (2002) S177-S182
57. Brennan F.M., Hayes A.L., Ciesielski C.J., et al. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis and Rheumatism 46 (2002) 31-41
58. Paulus H.E., Machleder H.I., Levine S., et al. Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage. Arthritis and Rheumatism 20 (1977) 1249-1262
59. Ueo T., Tanaka S., Tominaga Y., et al. The effect of thoracic duct drainage on lymphocyte dynamics and clinical symptoms in patients with rheumatoid arthritis. Arthritis and Rheumatism 22 (1979) 1405-1412
60. Vaughan J.H., Fox R.I., Abresch R.J., et al. Thoracic duct drainage in rheumatoid arthritis. Clinical and Experimental Immunology 58 (1984) 645-653
61. Tak P.P., Smeets T.J., Daha M.R., et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis and Rheumatism 40 (1997) 217-225
62. Bucht A., Larsson P., Weisbrot L., et al. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clinical and Experimental Immunology 103 (1996) 357-367
63. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31 (1988) 315-324
64. Singh J.A., Pando J.A., Tomaszewski J., and Schumacher H.R. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naive patients. The Journal of Rheumatology 31 (2004) 1281-1285
65. Jakubzick C., Choi E.S., Kunkel S.L., et al. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1- and Th2-type pulmonary granuloma fibroblasts. The American Journal of Pathology 162 (2003) 1475-1486
66. Kaufman J., Sime P.J., and Phipps R.P. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-gamma and IL-13, and implications for fibrosis. Journal of Immunology (Baltimore, Md.: 1950) 172 (2004) 1862-1871
67. Chiaramonte M.G., Donaldson D.D., Cheever A.W., and Wynn T.A. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. The Journal of Clinical Investigation 104 (1999) 777-785
68. Relic B., Guicheux J., Mezin F., et al. Il-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. Journal of Immunology (Baltimore, Md.: 1950) 166 (2001) 2775-2782
69. Bucala R., Ritchlin C., Winchester R., and Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. The Journal of Experimental Medicine 173 (1991) 569-574
70. Parsonage G., Falciani F., Burman A., et al. Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. Thrombosis and Haemostasis 90 (2003) 688-697
71. Weyand C.M., and Goronzy J.J. Ectopic germinal center formation in rheumatoid synovitis. Annals of the New York Academy of Sciences 987 (2003) 140-149
72. Machold K.P., Nell V.P., Stamm T.A., et al. The Austrian Early Arthritis Registry. Clinical and Experimental Rheumatology 21 (2003) S113-S117
73. Speyer I., Hazes J.M., and Breedveld F.C. Recruitment of patients with early rheumatoid arthritis - the Netherlands experience. The Journal of Rheumatology, Supplement 44 (1996) 84-85
74. Raza K., Breese M., Nightingale P., et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. The Journal of Rheumatology 32 (2005) 231-238
75. Visser H., le Cessie S., Vos K., et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism 46 (2002) 357-365
76. Green M., Marzo-Ortega H., McGonagle D., et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis and Rheumatism 42 (1999) 2184-2188
77. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism 43 (2000) 155-163
78. Goldbach-Mansky R., Lee J., McCoy A., et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Research 2 (2000) 236-243
79. Nell V.P., Machold K.P., Stamm T.A., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Annals of the Rheumatic Diseases 64 (2005) 1731-1736
80. Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism 43 (2000) 1831-1835
81. Meyer O., Labarre C., Dougados M., et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Annals of the Rheumatic Diseases 62 (2003) 120-126
82. Mottonen T., Hannonen P., Korpela M., et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis and Rheumatism 46 (2002) 894-898
83. Nell V.P., Machold K.P., Eberl G., et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43 (2004) 906-914
84. Feldmann M., and Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 9 (2003) 1245-1250
85. Choo-Kang B.S., Hutchison S., Nickdel M.B., et al. TNF-blocking therapies: an alternative mode of action?. Trends in Immunology 26 (2005) 518-522
86. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine 350 (2004) 2572-2581
87. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The New England Journal of Medicine 353 (2005) 1114-1123
88. Taylor P.C., Steuer A., Gruber J., et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis and Rheumatism 50 (2004) 1107-1116
89. Brown A.K., Wakefield R.J., Conaghan P.G., et al. New approaches to imaging early inflammatory arthritis. Clinical and Experimental Rheumatology 22 (2004) S18-S25